PRTA

Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B

Prothena sells amyloidosis portfolio to Novo Nordisk for up to $1.2 billion

Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion

Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena's ATTR Amyloidosis Programme

Strength Seen in Prothena (PRTA): Can Its 7.3% Jump Turn into More Strength?

Prothena: Well-Positioned In Parkinson's And Alzheimer's